Access the full text.
Sign up today, get DeepDyve free for 14 days.
(2013)
Alopecia With Endocrine Therapies in Patients With Cancer
L. Gallicchio, Carla Calhoun, K. Helzlsouer (2013)
Aromatase inhibitor therapy and hair loss among breast cancer survivorsBreast Cancer Research and Treatment, 142
N. Kluger, W. Jacot, E. Frouin, V. Rigau, S. Poujol, O. Dereure, B. Guillot, G. Romieu, D. Bessis (2012)
Permanent scalp alopecia related to breast cancer chemotherapy by sequential fluorouracil/epirubicin/cyclophosphamide (FEC) and docetaxel: a prospective study of 20 patients.Annals of oncology : official journal of the European Society for Medical Oncology, 23 11
A. Freites-Martinez, J. Shapiro, Donald Chan, M. Fornier, S. Modi, D. Gajria, S. Dusza, S. Goldfarb, M. Lacouture (2018)
Endocrine Therapy–Induced Alopecia in Patients With Breast CancerJAMA Dermatology, 154
U. Ohnemus, M. Uenalan, J. Inzunza, J. Gustafsson, R. Paus (2006)
The hair follicle as an estrogen target and source.Endocrine reviews, 27 6
L. Moscetti, M. Fabbri, I. Sperduti, Nelli Fabrizio, P. Frittelli, A. Massari, L. Pompei, G. D'Auria, E. Pofi, E. Ruggeri (2015)
Adjuvant Aromatase Inhibitor Therapy in Early Breast Cancer: What Factors Lead Patients to Discontinue Treatment?Tumori Journal, 101
D. Betticher, G. Delmore, U. Breitenstein, S. Anchisi, Beatrice Zimmerli-Schwab, A. Müller, R. Moos, Anne Hügli-Dayer, H. Schefer, S. Bodenmann, V. Bühler, R. Trueb (2013)
Efficacy and tolerability of two scalp cooling systems for the prevention of alopecia associated with docetaxel treatmentSupportive Care in Cancer, 21
B. Riedel-Baima, A. Riedel (2008)
Female pattern hair loss may be triggered by low oestrogen to androgen ratio.Endocrine regulations, 42 1
Patrick Vexiau, C. Chaspoux, Philippe Boudou, Jean Fiet, C. Jouanique, N. Hardy, P. Reygagne (2002)
Effects of minoxidil 2% vs. cyproterone acetate treatment on female androgenetic alopecia: a controlled, 12‐month randomized trialBritish Journal of Dermatology, 146
M. Harakalova, J. Harssel, P. Terhal, Stef Lieshout, K. Duran, I. Renkens, D. Amor, L. Wilson, E. Kirk, C. Turner, D. Shears, S. García-Miñaúr, M. Lees, A. Ross, H. Venselaar, G. Vriend, H. Takanari, M. Rook, M. Heyden, F. Asselbergs, H. Breur, M. Swinkels, I. Scurr, S. Smithson, N. Knoers, J. Smagt, I. Nijman, W. Kloosterman, M. Haelst, G. Haaften, E. Cuppen (2012)
Dominant missense mutations in ABCC9 cause Cantú syndromeNature Genetics, 44
K. Münstedt, N. Manthey, S. Sachsse, H. Vahrson (1997)
Changes in self-concept and body image during alopecia induced cancer chemotherapySupportive Care in Cancer, 5
M. Miteva, C. Misciali, P. Fanti, C. Vincenzi, P. Romanelli, A. Tosti (2011)
Permanent Alopecia After Systemic Chemotherapy: A Clinicopathological Study of 10 CasesThe American Journal of Dermatopathology, 33
R. Trüeb (2007)
Chemotherapy-Induced Anagen Effluvium: Diffuse or Patterned?Dermatology, 215
A. McGuire, James Brown, C. Malone, R. Mclaughlin, M. Kerin (2015)
Effects of Age on the Detection and Management of Breast CancerCancers, 7
E. McGarvey, L. Baum, R. Pinkerton, L. Rogers (2001)
Psychological sequelae and alopecia among women with cancer.Cancer practice, 9 6
Opinion EDITORIAL Minoxidil for Endocrine Therapy–Induced Alopecia in Women With Breast Cancer—Saint Agatha’s Blessing? Ralph M. Trüeb, MD Guard us against breast cancer and other afflictions of women, genetic alopecia-like, both clinically and on trichoscopic exami- and inspire us to overcome adversity. nation;negativeimpactonqualityoflifewassignificant;andtopi- From a prayer to St Agatha of Sicily, cal minoxidil improved alopecia in 80% of treated patients. Patron Saint for women Androgenetic alopecia is characterized by progressive short- with breast cancer ening of the duration of anagen with successive hair cycles, lead- ing to decreased numbers of hair in anagen at any given time, Worldwide, breast cancer is the most common invasive can- and progressive follicular miniaturization with conversion of ter- cer in women, affecting about 12%. The incidence has signifi- minal to vellus-like follicles. The result is increased shedding cantly increased since the 1970s; however, with the advances of short-lived telogen hairs, while the affected hair follicles pro- and sophistication in diagno- duce shorter, finer hairs that cover the scalp poorly. Although sis and treatment, survival androgens have dominated endocrinologic research into an- Related article page 670 rates have become high, with drogenetic alopecia, and androgen metabolism and the andro- between 80% and 90% of
JAMA Dermatology – American Medical Association
Published: Jun 11, 2018
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.